LitCovid-sentences  

PMC:7534795 / 116643-120799 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T710 0-70 Sentence denotes 9 When and how to intervene with n-3 PUFAs in the context of COVID-19
T711 71-292 Sentence denotes An important aspect in considering n-3 PUFAs as adjunctive therapy in critically or severe ill patients is the time of intervention, duration of treatment, dose, composition of the preparation and route of administration.
T712 293-446 Sentence denotes The type and intensity of supportive treatment required by a patient is dependent upon the severity of disease and the possible need for hospitalization.
T713 447-613 Sentence denotes Existing literature demonstrates it may take weeks or months for standard doses of n-3 PUFAs to exert a biological effect due to a gradual replacement of membrane AA.
T714 614-803 Sentence denotes It has been hypothesized the acute supplementation with n-3 PUFAs may influence the inflammatory response in critically ill patients, particularly those with ALI (Martin & Stapleton, 2010).
T715 804-1035 Sentence denotes For example, a randomized clinical trial showed daily enteral feeding of critically ill ALI patients with elevated levels EPA, DHA and gamma-linolenic acid significantly reduced lung inflammation and improved oxygenation by 4 days.
T716 1036-1184 Sentence denotes This was associated with a decreased duration of mechanical ventilation, ICU length of stay and mortality (Gadek et al., 1999; Singer et al., 2006).
T717 1185-1595 Sentence denotes In a trial conducted by Pontes-Arruda et al. who studied patients with sepsis requiring mechanical ventilation, a diet enriched with EPA, gamma-linolenic acid and antioxidants delivered at a constant rate during a minimum of 4 days contributed to better ICU and hospital outcomes, oxygenation status, ventilator-free days and was associated with lower mortality at 28-day interval (Pontes-Arruda et al., 2006).
T718 1596-1713 Sentence denotes There are many studies suggesting the beneficial effects of parenteral fish oil emulsions in critically ill patients.
T719 1714-1946 Sentence denotes For example, parenteral supplementation of severe ill patients with lipid emulsions containing fish oil was associated with reduced inflammation, improved gas exchange and shorter length of ICU and hospital stay (Zhao & Wang, 2018).
T720 1947-2133 Sentence denotes In a study by Mayer et al., patients with sepsis were randomized in an open-label trial to receive an omega-3 FA rich lipid emulsion or a standard omega-6 rich lipid emulsion for 5 days.
T721 2134-2406 Sentence denotes Within 2 days of fish oil infusion, free n-3 fatty acids increased and the n-3/n-6 ratio was reversed favoring EPA and DHA over AA, with rapid incorporation of n-3 fatty acids into mononuclear leukocyte membranes and reaching maximum effect in 3 days (Mayer et al., 2003).
T722 2407-2558 Sentence denotes Furthermore, a parenteral lipid emulsion enriched in n-3 PUFA for 7 days was found to reduce acetic acid-induced colitis in rats (Campos et al., 2002).
T723 2559-2917 Sentence denotes In a randomized controlled trial conducted by Wang et al., patients with severe acute pancreatitis were randomly assigned to receive parenteral nutrition for 5 days containing similar amounts of amino acids, glucose and fat but different lipid compositions: the control group received a soybean oil-based fat solution and the omega-3 group received fish oil.
T724 2918-3119 Sentence denotes Interestingly, patients treated with the fish oil or n-3 PUFAs had a markedly lower inflammatory marker CRP and better oxygenation index after 5 days of parenteral nutrition (Wang, Li, Li, & Li, 2008).
T725 3120-3301 Sentence denotes Together, these studies demonstrated that acute enteral or parenteral administration of n-3 PUFAs in the setting of severe illness could significantly improve the clinical outcomes.
T726 3302-3634 Sentence denotes Notably, it has been shown that fish oil emulsions containing substantial amounts of EPA and DHA have an excellent safety record in both critically ill adults and children (Calder, 2009, Calder, 2019; Nandivada, Fell, Gura, & Puder, 2016) making them a suitable candidate for use in severe stress conditions as in COVID-19 patients.
T727 3635-3849 Sentence denotes However, with the research that has been completed to date, it is not possible to definitively determine the dose, route of administration and the best timing to intervene with n-3 PUFAs in the setting of COVID-19.
T728 3850-4156 Sentence denotes More research is undoubtedly needed before definitive recommendations about the routine use of n-3 PUFAs in the context of COVID-19 can be made particularly that dosing data and pharmacokinetics studies of both enteral and parenteral n-3 PUFAs in critically ill patients are highly variable and incomplete.